Older and younger patients with advanced renal cell carcinoma (RCC) derive similar benefit from sorafenib, data suggest.
Tim Eisen, PhD, of Addenbrooke’s Hospital and the University of Cambridge, U.K., and colleagues studied data from a randomized phase 3 trial—the Treatment Approach in Renal Cancer Global Evaluation Trial (TARGET). The trial compared sorafenib and placebo in 115 patients aged 70 years and older and 787 who were aged 69 years and younger.
Among sorafenib-treated patients, median progression-free survival was 23.9 weeks for the younger group and 26.3 weeks for the older group, the investigators reported in the Journal of the National Cancer Institute (2008; published online ahead of print).
In addition, the proportion of patients who had a complete or partial response or stable disease was 84.3% and 83.5% for the older and younger groups, respectively.
“In this retrospective subgroup analysis of TARGET data, sorafenib treatment appeared to improve outcomes among patients with advanced renal cell carcinoma, regardless of age,” the authors wrote. They added that they observed “no notable difference in the frequency or severity of sorafenib-related toxicity between younger and older patients.”